S.I. No. 727/2022 - European Union (Clinical Trials on Medicinal Products for Human Use) (Principal) (Amendment) Regulations 2022

S.I. No. 727/2022 - European Union (Clinical Trials on Medicinal Products for Human Use) (Principal) (Amendment) Regulations 2022 Skip to content Disclaimer Feedback Helpdesk Gaeilge Léim go dtí an t-ábhar Séanadh Aiseolas Deasc chabhrach English Gaeilge English Produced by the Office of the Attorney General Táirgthe ag Oifig an Ard-Aighne Home Legislation Acts of the Oireachtas Statutory Instruments Pre-1922 Legislation Constitution External Resources Bills (Houses of the Oireachtas) Iris Oifigiúil / Official Gazette Revised Acts (LRC) Classified List of Legislation (LRC) Translations (acts.

1. ie)Translations (Houses of the Oireachtas) Government Publications for Sale EU Law (EUR-Lex) FAQ Disclaimer Feedback Helpdesk Search Baile Reachtaíocht Achtanna an Oireachtais Ionstraimí Reachtúla Reachtaíocht Réamh-1922 Bunreacht Acmhainní Seachtracha Billí (Tithe an Oireachtais) Iris Oifigiúil Achtanna Athbhreithnithe (CAD) (An Coimisiún um Athchóiriú an Dlí) Liosta Rangaithe Reachtaíochta Aistriúcháin (achtanna.
2. ie)Aistriúcháin (Tithe an Oireachtais) Foilseacháin Rialtais ar Díol Dlí AE (EUR-Lex) CCanna (Ceisteanna Coitianta) Séanadh Aiseolas Deasc chabhrach Cuardach TitleTeideal Year(
3. s)or rangeBliain nó blianta nó raon TypeCineál All Legislation Acts Statutory Instruments Advanced SearchCuardach Casta HomeBaile Statutory InstrumentsIonstraimí Reachtúla 2022 S.I. No. 727/2022 - European Union (Clinical Trials on Medicinal Products for Human Use) (Principal) (Amendment) Regulations 2022 S.I. No. 727/2022 - European Union (Clinical Trials on Medicinal Products for Human Use) (Principal) (Amendment) Regulations 2022 AmendmentsLeasuithe Download PDF Íoslódáil PDF Notice of the making of this Statutory Instrument was published in “Iris Oifigiúil” of 3rd January, 2023. I, STEPHEN DONNELLY, Minister for Health, in exercise of the powers conferred on me by section 3 of the European Communities Act 1972 (No. 27 of 1972) and for the purpose of giving further effect to Regulation (EC) No. 536/2014 of 16 April 20141 , hereby make the following regulations: 1. These Regulations may be cited as the European Union (Clinical Trials on Medicinal Products for Human Use) (Principal) (Amendment) Regulations 2022. 2. The European Union (Clinical Trials on Medicinal Products for Human Use) (Principal) Regulations 2022 ( S.I. No. 99 of 2022 ) are amended by inserting after Regulation 61 the following regulation: “61A. An application to which Regulation 61(
4. a)applies, and which relates to the whole State, shall be made to the National Office and the following fees shall be payable by the applicant to the National office: (
5. a)in the case of an application under Regulation 12 of the European Communities (Clinical Trials on Medicinal Products for Human Use) Regulations 2004— (
6. i)€1,500 for commercial trials, or (
7. ii)€150 for non-commercial trials, in connection with each such application, with no fee for each additional trial site to which the application relates; and (
8. b)in the case of a notification of amendment under Regulations 21